Welcome to our dedicated page for Briacell Therapeutics SEC filings (Ticker: BCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company focused on novel cancer immunotherapies. Through these filings, investors can review official disclosures on BriaCell’s corporate structure, securities listings, subsidiaries, and selected financial information.
BriaCell’s SEC documents include current reports on Form 8-K, which may describe material events such as subsidiary activities and regulatory filings made with Canadian securities commissions. For example, a recent Form 8-K notes that BriaPro Therapeutics Corp., a two-thirds owned subsidiary of BriaCell, filed unaudited condensed interim consolidated financial statements and management’s discussion and analysis with provincial regulators, and these materials were furnished as exhibits to the 8-K.
On this page, users can access BriaCell’s periodic and current reports as they become available through EDGAR, including Forms 10-K and 10-Q when filed, which typically provide details on clinical development programs, risk factors, and management’s discussion of operations. In addition, Form 4 and related insider transaction reports, when filed, can offer insight into share transactions by directors, officers, and significant shareholders.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, highlight important risk disclosures, and point out items relevant to BriaCell’s oncology pipeline, such as descriptions of the Bria-IMT, Bria-OTS, and Bria-OTS+ platforms or the BriaPro small-molecule initiatives. Real-time updates ensure that new BCTX filings from EDGAR are added promptly, while AI-generated overviews help readers navigate lengthy documents and focus on information that matters for understanding BriaCell’s regulatory and financial profile.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerates late-stage cancer trials. For the three months ended January 31, 2026, net loss was $7.3M versus $6.3M a year earlier, driven mainly by higher research and development spending.
Research, development, and clinical trial expenses for the half-year rose to $12.7M from $9.4M, reflecting intensive investment in the pivotal Phase 3 Bria‑IMT™ metastatic breast cancer study and the Bria‑OTS™ Phase 1/2a program. General and administrative costs were relatively stable at $3.1M for the six-month period.
The company strengthened its balance sheet, ending January 31, 2026 with cash and cash equivalents of $29.9M and positive working capital of $29.0M, helped by $27.9M in net equity financing during the half-year and a public offering of approximately $30.0M in gross proceeds. However, accumulated deficit reached $127.2M, and management states that uncertainty around securing future financing raises substantial doubt about BriaCell’s ability to continue as a going concern.
BriaCell Therapeutics Corp. held its Annual General and Special Meeting of Shareholders on March 5, 2026. Shareholders owning 3,502,695 common shares were present in person or by proxy, out of 7,250,487 common shares issued and outstanding as of the January 26, 2026 record date.
Shareholders ratified the appointment of MNP LLP as auditors, with 3,431,761 votes for and 70,934 withheld. Six directors were elected, including Dr. Jane Gross, Mr. Jamieson Bondarenko, Dr. William V. Williams, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg.
Shareholders also re-approved the Company’s Omnibus Equity Incentive Plan, with 1,524,081 votes for, 362,949 against, and 1,615,665 broker non-votes, maintaining the Company’s existing framework for equity-based compensation.
BriaCell Therapeutics Corp. filed a Form 25 notifying removal of its Warrant class from listing and registration on the Nasdaq Stock Market LLC.
Nasdaq certified compliance with 17 CFR 240.12d2-2 procedures to strike the class and the filing states the issuer complied with the Exchange's voluntary withdrawal requirements. The notice is signed by Tara Petta, Director.
BriaCell Therapeutics Corp. has entered an asset purchase agreement with its majority‑owned subsidiary BriaPro Therapeutics Corp., transferring BriaCell’s exclusive license to develop and commercialize Soluble CD80 for cancer and related assets to BriaPro. As consideration, BriaPro will issue 23,972,589 BriaPro common shares, raising BriaCell’s ownership in BriaPro to about 78% after the transaction. BriaCell will also make available up to $3.0 million to BriaPro through a credit facility to fund research and development, with each drawdown subject to BriaCell’s approval. The deal is expected to close on or around March 12, 2026, subject to approval by disinterested BriaPro shareholders and receipt of an independent third‑party valuation confirming fair market value.
BriaCell Therapeutics Corp. has called its 2026 annual general and special meeting for March 5, 2026 in Toronto. Shareholders of record on January 26, 2026, representing 7,250,487 common shares, can vote in person or by proxy.
Investors will vote on appointing MNP LLP as auditor, electing six directors, and re-approving BriaCell’s rolling omnibus equity incentive plan, which allows equity awards up to 15% of shares outstanding, with additional caps for insiders and non-employee directors. The Board unanimously recommends voting “FOR” all three proposals.
BriaCell Therapeutics Corp. (BCTX) received a Schedule 13G filing from a group of Citadel-affiliated entities and Kenneth Griffin, disclosing a sizable passive stake in the company’s common shares.
The group reports beneficial ownership of 717,198 Shares, which represents 9.99% of BriaCell’s outstanding common shares. Within this, Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC may each be deemed to beneficially own 716,699 Shares (9.98% of the class), while Citadel Securities LLC and related entities may be deemed to beneficially own 499 Shares (0.0% of the class).
The reported percentages are based on 7,179,163 Shares outstanding, including 6,211,436 Shares outstanding as of January 15, 2026, 657,096 Shares issued upon voluntary warrant exercises by Citadel affiliates, and 310,631 Shares issuable upon conversion of warrants that are subject to a 9.99% beneficial ownership limitation.
BriaCell Therapeutics Corp. completed a public offering of 4,327,530 Common Units and 1,039,196 Pre-funded Units at $5.59 per Common Unit and $5.589 per Pre-funded Unit, generating aggregate gross proceeds of approximately $30 million before fees and expenses. Each Common Unit includes one common share and one five-year warrant, while each Pre-funded Unit includes a pre-funded warrant priced at $0.001 per share plus one warrant; each warrant is exercisable at $6.93 per share and trades on Nasdaq under the symbol BCTXL. The company also issued placement agent warrants to purchase up to 161,001 common shares at $8.385 per share and paid the placement agent a 6.25% cash fee on gross proceeds. BriaCell plans to use the net proceeds for working capital, general corporate purposes, and to advance its business objectives, with all securities issued under effective Form S-1 registration statements.
BriaCell Therapeutics Corp. reported that its two-thirds owned subsidiary, BriaPro Therapeutics Corp., has filed unaudited condensed interim consolidated financial statements and a management’s discussion and analysis for the three-month period ended October 31, 2025 with securities regulators in British Columbia and Alberta. These BriaPro financial statements and the related discussion are attached to the report as Exhibits 99.1 and 99.2 and are incorporated by reference for informational purposes only. The company notes that this information is being furnished under Regulation FD and is not considered filed for liability purposes under U.S. securities laws.